KZA 0.00% 8.0¢ kazia therapeutics limited

Kazia April 2021 Licensing EVT801 UpdateKazia CEO, Dr James...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,165 Posts.
    lightbulb Created with Sketch. 862
    Kazia April 2021 Licensing EVT801 Update
    Kazia CEO, Dr James Garner discusses the in-licensing of EVT801 - a small-molecule inhibitor of VEGFR3 - from Evotec (FRA: EVT), a leading European drug discovery and development company.


    Congratulations to Dr James Garner and the Kazia Team on this fabulous drug EVT801 in licencing acquisition and ongoing collaboration with Evotec.

    This is now posted on the Kazia website.

    Regards.
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.